Original research
par
Nielsen, Suzanne et al
Date de publication
2021
Géographie
Australia
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
Although most opioid-related mortality in Australia involves prescription opioids, most research to understand the impact of naloxone supply on opioid-related mortality has focused upon people who inject heroin. We aimed to examine the cost and probable impact of up-scaling naloxone supply to people who are prescribed opioids.
Constatations/points à retenir
In Australia, scaling-up take-home naloxone by 2030 to reach 90% of people prescribed daily doses of ≥ 50 mg of oral morphine equivalents would be cost-effective and save more than 650 lives.
La conception ou méthodologie de recherche
Four scenarios were compared with a baseline scenario (the current status quo): naloxone scale-up between 2020 and 2030 to reach 30 or 90% coverage by 2030, among the subgroups of people prescribed either ≥ 50 or ≥ 100 mg of oral morphine equivalents (OME).
Mots clés
Mortality
Harm reduction
Policy/Regulatory
About prescribers
